Phase-I and randomized phase-II trial of panobinostat in combination with ICE (Ifosfamide, carboplatin, etoposide) in relapsed or refractory classical hodgkin lymphoma

Bei Hu, Anas Younes, Jason R. Westin, Francesco Turturro, Linda Claret, Lei Feng, Nathan Fowler, Sattva Neelapu, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Felipe Samaniego, Luis E. Fayad, Amanda R. Copeland, Loretta J. Nastoupil, Yago Nieto, Michelle A. Fanale, Yasuhiro Oki

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE (Schedule A). No DLT was observed at 30 mg. However, frequent (84%) grade-4 thrombocytopenia during second week prompted us to omit the second week of panobinostat 30mg (Schedule B) for phase II, where this regimen was compared to ICE. In the randomized phase-II study, CR was seen in 9/11 (82%) and 8/12 (67%) for P-ICE and ICE, respectively (p=.64). Grade-4 neutropenia (55% vs. 8%) and thrombocytopenia (100% vs. 33%) were more common in P-ICE. In summary, combination therapy using panobinostat produced high CR rate at the cost of greater bone marrow toxicity. Investigation of panobinostat with less myelosuppressive agents is of interest.

Original languageEnglish (US)
Pages (from-to)863-870
Number of pages8
JournalLeukemia and Lymphoma
Volume59
Issue number4
DOIs
StatePublished - Aug 10 2018

Keywords

  • Classical Hodgkin lymphoma
  • Histone deacetylase inhibitors
  • Panobinostat
  • Phase-I study
  • Phase-II study
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase-I and randomized phase-II trial of panobinostat in combination with ICE (Ifosfamide, carboplatin, etoposide) in relapsed or refractory classical hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this